Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
BACKGROUND AND OBJECTIVE: This paper was based on a literature search of PubMed and Scielo databases using the keywords "Flavonoids, Neuroprotection, Quercetin, Rutin, Isoquercitrin, Alzheimer, Parkinson, Huntington" and combinations of all the words.
METHOD: We collected relevant publications, during the period of 2000 to 2016, emphasizing in vivo and in vitro studies with neurological assessment of flavonol's potentials, as well as classifying studies according to evidence levels, in order to elucidate evidence-based literature and its application on clinical research. In addition, we highlight the importance of flavonols in modern research fields, indicating their neuroprotective potential and use thereof as preventive and therapeutic treatment of numerous neurodegenerative disease. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, represent worldwide a major health problem with great financial impact. They are multifactorial diseases, hallmarked by similar pathogenesis that covers conditions such as oxidative stress, formation of free radicals, abnormal protein dynamics (degradation and aggregation), mitochondrial dysfunction, lipid peroxidation and cellular death or senescence. Flavonols are polyphenolic compounds, widely distributed in the plant kingdom and found in high concentrations in vegetables, fruits and teas. Their neuroprotective effects are mainly related to their antioxidant, anti-proliferative and anti-inflammatory properties.
CONCLUSION: It was this paper's intention to contribute with an evidence analysis of recent studies approaching neuroprotective effects of flavonols and the potential to conduct human clinical studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - 17(2018), 1 vom: 26. Apr., Seite 34-42 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bombardi Duarte, Ana Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer |
|---|
| Anmerkungen: |
Date Completed 31.05.2019 Date Revised 31.05.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871527317666171221110139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27932409X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27932409X | ||
| 003 | DE-627 | ||
| 005 | 20231225022711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527317666171221110139 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0931.xml |
| 035 | |a (DE-627)NLM27932409X | ||
| 035 | |a (NLM)29268692 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bombardi Duarte, Ana Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2019 | ||
| 500 | |a Date Revised 31.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: This paper was based on a literature search of PubMed and Scielo databases using the keywords "Flavonoids, Neuroprotection, Quercetin, Rutin, Isoquercitrin, Alzheimer, Parkinson, Huntington" and combinations of all the words | ||
| 520 | |a METHOD: We collected relevant publications, during the period of 2000 to 2016, emphasizing in vivo and in vitro studies with neurological assessment of flavonol's potentials, as well as classifying studies according to evidence levels, in order to elucidate evidence-based literature and its application on clinical research. In addition, we highlight the importance of flavonols in modern research fields, indicating their neuroprotective potential and use thereof as preventive and therapeutic treatment of numerous neurodegenerative disease. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, represent worldwide a major health problem with great financial impact. They are multifactorial diseases, hallmarked by similar pathogenesis that covers conditions such as oxidative stress, formation of free radicals, abnormal protein dynamics (degradation and aggregation), mitochondrial dysfunction, lipid peroxidation and cellular death or senescence. Flavonols are polyphenolic compounds, widely distributed in the plant kingdom and found in high concentrations in vegetables, fruits and teas. Their neuroprotective effects are mainly related to their antioxidant, anti-proliferative and anti-inflammatory properties | ||
| 520 | |a CONCLUSION: It was this paper's intention to contribute with an evidence analysis of recent studies approaching neuroprotective effects of flavonols and the potential to conduct human clinical studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alzheimer | |
| 650 | 4 | |a Parkinson | |
| 650 | 4 | |a animal models | |
| 650 | 4 | |a flavonoids | |
| 650 | 4 | |a huntington | |
| 650 | 4 | |a neurodegenerative. | |
| 650 | 7 | |a Flavonols |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 700 | 1 | |a Santana, Maycon Giovani |e verfasserin |4 aut | |
| 700 | 1 | |a di Camilo Orfali, Guilherme |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Carlos Tadeu Parisi |e verfasserin |4 aut | |
| 700 | 1 | |a Priolli, Denise Goncalves |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g 17(2018), 1 vom: 26. Apr., Seite 34-42 |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2018 |g number:1 |g day:26 |g month:04 |g pages:34-42 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527317666171221110139 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2018 |e 1 |b 26 |c 04 |h 34-42 | ||